Special Issue

Advanced Research in Anticancer Inhibitors and Targeted Therapy

Message from the Guest Editors

Rapidly advancing targeted cancer therapy has significantly improved treatment efficacy by selectively inhibiting oncogenic signaling pathways. Among these, histone deacetylase (HDAC) inhibitors, kinase inhibitors, and immune checkpoint inhibitors have demonstrated remarkable potential in both preclinical and clinical studies. However, the emergence of drug resistance, tumor heterogeneity, and adverse side effects pose substantial challenges to their clinical application. This Special Issue aims to explore novel anticancer inhibitors, their molecular mechanisms, and potential combination strategies to overcome resistance, seeking to provide novel insights into improving the effectiveness and durability of targeted cancer therapies. We welcome original research and review articles focusing on epigenetic therapy, small-molecule inhibitors, immune-based treatments, and new therapeutic targets. Studies employing biochemical, molecular, and cellular approaches to investigate drug efficacy, biomarker discovery, and resistance mechanisms are highly encouraged.

Guest Editors

Dr. Changmin Peng
School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA

Dr. Hassan Ebrahim
Department of Biomedical Sciences, Edward Via College of Osteopathic Medicine, Louisiana Campus, Monroe, LA 71203, USA

Deadline for manuscript submissions

31 October 2025

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/235264

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).